Interstitial lung disease (ILD) is a key prognostic factor in connective tissue disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective tissue disorder (MCTD), following the use of rituximab therapy.

Effects of rituximab in connective tissue disorders related interstitial lung disease / Lepri, G., Avouac, J., Airò, P., Anguita Santos, F., BELLANDO RANDONE, S., Blagojevic, J., Garcia Hernàndez, F., Gonzalez Nieto, J.A., Guiducci, S., Jordan, S., Limaye, V., Maurer, B., Selva O'Callaghan, A., Riccieri, V., Distler, O., MATUCCI CERINIC, M., Allanore, Y.. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 34 Suppl 100:(2016), pp. 181-185.

Effects of rituximab in connective tissue disorders related interstitial lung disease

MATUCCI CERINIC, MARCO;
2016-01-01

Abstract

Interstitial lung disease (ILD) is a key prognostic factor in connective tissue disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective tissue disorder (MCTD), following the use of rituximab therapy.
2016
Systemic Sclerosis
rituximab
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/154431
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 57
social impact